In this issue:
Disease-modifying effects of a novel cathepsin K inhibitor in OA
Ixekizumab for patients with nr-AxSpA
Risk of serious infection after initiating tofacitinib vs biologic DMARDs in RA
Five-year outcome of operative and nonoperative management of meniscal tear
Adverse events during oral colchicine use
Long term safety results of ixekizumab
ICI-induced inflammatory arthritis persists after immunotherapy cessation
Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis
Association of pain and steps per day in symptomatic knee OA
Please login below to download this issue (PDF)